We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04136353
Recruitment Status : Recruiting
First Posted : October 23, 2019
Last Update Posted : February 3, 2023
Sponsor:
Collaborators:
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Bayer
Cancer Trials Ireland
Canadian Cancer Trials Group
Memorial Sloan Kettering Cancer Center
Prostate Cancer Clinical Trials Consortium
Information provided by (Responsible Party):
University of Sydney

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 31, 2028
Estimated Study Completion Date : July 31, 2028